Implementing guidelines for the institutional use of factor VIIa (recombinant): A multidisciplinary solution

American Journal of Health-System Pharmacy

Volumn 63, Issue 17, 2006, Pages 1641-1646

  Rudisill, Celeste N ^a,b   Hockman, Rebecca H ^c   DeGregory, Kathlene A ^d   Mutnick, Alan H ^b   Macik, Barbara Gail ^e  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c Department of Pharmacy Hematology Oncology

^d Hematology/Oncology   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; GLYCOPROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDICATION; DRUG USE; EDUCATION; HEMOPHILIA; HUMAN; LIVER DISEASE; OFF LABEL DRUG USE; PERSONNEL MANAGEMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 33748771529     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060093     Document Type: Article

References (12)

1. NovoSeven (coagulation factor VIIa [recombinant]) package insert. Princeton, NJ: Novo Nordisk; 2005 Jun.
2. Lam MS, Sims-McCallum RP. Recombinant factor VIIa in the treatment of nonhemophiliac bleeding. Ann Pharmacother. 2005; 39:885-91.
3. Hoffman M, Monroe DM III. A cell-based model of hemostasis. Thromb Haemost. 2001; 85:958-65.
4. O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-8.
5. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002; 137:884-8.
6. Tobias JD, Groeper K, Berkenbosch JW. Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J. 2003; 96:12-6.
7. Brown J, Emerick K, Brown D et al. Recombinant factor VII improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr. 2003; 37:268-72.
8. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003; 361:201-5.
9. [Erratum, Lancet. 2003; 361:1138.]
10. Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005; 352:777-85.
11. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63:123-38.
12. Phillips MS, Cayman JE, Todd MW. ASHP guidelines on medication-use evaluation. Am J Health-Syst Pharm. 1996; 53:1953-5.